TWI572597B - 二甲基－苯甲酸化合物 - Google Patents
二甲基－苯甲酸化合物 Download PDFInfo
- Publication number
- TWI572597B TWI572597B TW102120796A TW102120796A TWI572597B TW I572597 B TWI572597 B TW I572597B TW 102120796 A TW102120796 A TW 102120796A TW 102120796 A TW102120796 A TW 102120796A TW I572597 B TWI572597 B TW I572597B
- Authority
- TW
- Taiwan
- Prior art keywords
- dimethyl
- amino
- methyl
- benzoic acid
- mmol
- Prior art date
Links
- RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical class CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 82
- 150000003839 salts Chemical class 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 28
- 201000008482 osteoarthritis Diseases 0.000 claims description 16
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 15
- 208000002193 Pain Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 212
- 238000006243 chemical reaction Methods 0.000 description 122
- 239000000243 solution Substances 0.000 description 111
- 238000002360 preparation method Methods 0.000 description 103
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 99
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 98
- 230000015572 biosynthetic process Effects 0.000 description 98
- 238000003786 synthesis reaction Methods 0.000 description 97
- 235000019439 ethyl acetate Nutrition 0.000 description 96
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 91
- 239000011541 reaction mixture Substances 0.000 description 91
- 239000012044 organic layer Substances 0.000 description 71
- 230000002829 reductive effect Effects 0.000 description 69
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 53
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 46
- 229910052938 sodium sulfate Inorganic materials 0.000 description 35
- 235000011152 sodium sulphate Nutrition 0.000 description 35
- 239000002904 solvent Substances 0.000 description 34
- 238000003818 flash chromatography Methods 0.000 description 32
- 239000000203 mixture Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- 101001117509 Homo sapiens Prostaglandin E2 receptor EP4 subtype Proteins 0.000 description 23
- 102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 23
- 229910052757 nitrogen Inorganic materials 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 18
- 239000003960 organic solvent Substances 0.000 description 18
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 14
- 239000005557 antagonist Substances 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 9
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 9
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- -1 porphyrin amides Chemical class 0.000 description 9
- WOJKYHBOHSQZDW-UHFFFAOYSA-N 4-[[6-(4-hydroxypiperidin-1-yl)-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoic acid Chemical compound CC1=CC=C(N2CCC(O)CC2)N=C1C(=O)NC1=C(C)C=C(C(O)=O)C=C1C WOJKYHBOHSQZDW-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 206010003246 arthritis Diseases 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- SEENCYZQHCUTSB-UHFFFAOYSA-N 5-bromo-2-methylbenzoic acid Chemical compound CC1=CC=C(Br)C=C1C(O)=O SEENCYZQHCUTSB-UHFFFAOYSA-N 0.000 description 5
- YSSBNOCWEHENNX-UHFFFAOYSA-N CCCCCCCCC(C(C)(C)C)C(C)(C)OCC1CNCCC1 Chemical compound CCCCCCCCC(C(C)(C)C)C(C)(C)OCC1CNCCC1 YSSBNOCWEHENNX-UHFFFAOYSA-N 0.000 description 5
- 101001073427 Homo sapiens Prostaglandin E2 receptor EP1 subtype Proteins 0.000 description 5
- 101001117519 Homo sapiens Prostaglandin E2 receptor EP2 subtype Proteins 0.000 description 5
- 101001117517 Homo sapiens Prostaglandin E2 receptor EP3 subtype Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 description 5
- 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- QQCLNRPRQRDMCK-UHFFFAOYSA-N methyl 2,4-dimethylbenzoate Chemical compound COC(=O)C1=CC=C(C)C=C1C QQCLNRPRQRDMCK-UHFFFAOYSA-N 0.000 description 5
- 229940095102 methyl benzoate Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- RPFAUCIXZGMCFN-UHFFFAOYSA-N 5-bromo-2-(trifluoromethyl)pyridine Chemical group FC(F)(F)C1=CC=C(Br)C=N1 RPFAUCIXZGMCFN-UHFFFAOYSA-N 0.000 description 4
- ODSPBBWQVLWOPG-UHFFFAOYSA-N 6-chloro-3-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=C(Cl)N=C1C(O)=O ODSPBBWQVLWOPG-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000007987 MES buffer Substances 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- UBXTUCGVTZERIW-UHFFFAOYSA-N ethyl 4-[(6-chloro-3-methylpyridine-2-carbonyl)amino]-3,5-dimethylbenzoate Chemical compound CC1=CC(C(=O)OCC)=CC(C)=C1NC(=O)C1=NC(Cl)=CC=C1C UBXTUCGVTZERIW-UHFFFAOYSA-N 0.000 description 4
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- RQTXEJYGOHZSIW-UHFFFAOYSA-N methyl 2,3-dimethylbenzoate Chemical compound COC(=O)C1=CC=CC(C)=C1C RQTXEJYGOHZSIW-UHFFFAOYSA-N 0.000 description 4
- WVWZECQNFWFVFW-UHFFFAOYSA-N methyl 2-methylbenzoate Chemical compound COC(=O)C1=CC=CC=C1C WVWZECQNFWFVFW-UHFFFAOYSA-N 0.000 description 4
- JLLLNXJTBCOQFL-UHFFFAOYSA-N methyl 3-[(6-chloro-3-methylpyridine-2-carbonyl)amino]-2,4-dimethylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(NC(=O)C=2C(=CC=C(Cl)N=2)C)=C1C JLLLNXJTBCOQFL-UHFFFAOYSA-N 0.000 description 4
- RIFHBFZPEGIOEG-UHFFFAOYSA-N methyl 4-[(6-chloro-3-methylpyridine-2-carbonyl)amino]-3,5-dimethylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC(C)=C1NC(=O)C1=NC(Cl)=CC=C1C RIFHBFZPEGIOEG-UHFFFAOYSA-N 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- QITBKIGOBMSJBN-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-5,5,5-trifluoro-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)NC(CC(C)C(F)(F)F)C(O)=O)C3=CC=CC=C3C2=C1 QITBKIGOBMSJBN-UHFFFAOYSA-N 0.000 description 3
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZLWNQQRXLBWJDV-UHFFFAOYSA-N CCCCCCCCC(C(C)(C)C)C(C)(C)OC1CCNCC1 Chemical compound CCCCCCCCC(C(C)(C)C)C(C)(C)OC1CCNCC1 ZLWNQQRXLBWJDV-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 102100035842 Prostaglandin E2 receptor EP1 subtype Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000013262 cAMP assay Methods 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940111134 coxibs Drugs 0.000 description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000003821 enantio-separation Methods 0.000 description 3
- GEMKGDSDLYAIRK-UHFFFAOYSA-N ethyl 4-amino-3,5-dimethylbenzoate Chemical compound CCOC(=O)C1=CC(C)=C(N)C(C)=C1 GEMKGDSDLYAIRK-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- ARSRTLJLMXSRPV-UHFFFAOYSA-N methyl 4-amino-3,5-dimethylbenzoate Chemical compound COC(=O)C1=CC(C)=C(N)C(C)=C1 ARSRTLJLMXSRPV-UHFFFAOYSA-N 0.000 description 3
- XWPSWOKQWBNRDW-UHFFFAOYSA-N methyl 6-chloro-3-methylpyridine-2-carboxylate Chemical compound COC(=O)C1=NC(Cl)=CC=C1C XWPSWOKQWBNRDW-UHFFFAOYSA-N 0.000 description 3
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 2
- BIACWLGCCVBYNE-UHFFFAOYSA-N 1-iodo-2,4-dimethyl-3-nitrobenzene Chemical compound CC1=CC=C(I)C(C)=C1[N+]([O-])=O BIACWLGCCVBYNE-UHFFFAOYSA-N 0.000 description 2
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 2
- IFMWWVGVDOTBNN-UHFFFAOYSA-N 2-chloro-2,3,3-trimethylbutane Chemical compound CC(C)(C)C(C)(C)Cl IFMWWVGVDOTBNN-UHFFFAOYSA-N 0.000 description 2
- KBOBQLJBYKKAPN-UHFFFAOYSA-N 2-chloro-2-methylhexane Chemical compound CCCCC(C)(C)Cl KBOBQLJBYKKAPN-UHFFFAOYSA-N 0.000 description 2
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 2
- BOGXRDSVWHWIFV-UHFFFAOYSA-N 3-[[3-(4-hydroxypiperidin-1-yl)naphthalene-1-carbonyl]amino]-2,4-dimethylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(C)=C1NC(=O)C1=CC(N2CCC(O)CC2)=CC2=CC=CC=C12 BOGXRDSVWHWIFV-UHFFFAOYSA-N 0.000 description 2
- CXBLQEIODBBSQD-UHFFFAOYSA-N 4-methylpiperidin-4-ol Chemical compound CC1(O)CCNCC1 CXBLQEIODBBSQD-UHFFFAOYSA-N 0.000 description 2
- SWSCMXZZHFRZLX-UHFFFAOYSA-N 5-bromo-2-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(Br)=CC=C1C(F)(F)F SWSCMXZZHFRZLX-UHFFFAOYSA-N 0.000 description 2
- PEXAZYDITWXYNJ-UHFFFAOYSA-N 5-bromo-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC=C1F PEXAZYDITWXYNJ-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- MWBNCZHVEXULBD-ZDUSSCGKSA-N Benzoic acid, 4-[(1s)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]- Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC=C(F)C=C1 MWBNCZHVEXULBD-ZDUSSCGKSA-N 0.000 description 2
- YLZOUGBRUMHPCT-UHFFFAOYSA-N CC(C=CC(C(OC)=O)=C1C)=C1N=CC(C=C(C=C1)N2CC(CO)CCC2)=C1F Chemical compound CC(C=CC(C(OC)=O)=C1C)=C1N=CC(C=C(C=C1)N2CC(CO)CCC2)=C1F YLZOUGBRUMHPCT-UHFFFAOYSA-N 0.000 description 2
- BKOMJKYHNLXHQO-UHFFFAOYSA-N CC1=CC(=CC(=C1N=CC2=C(C=CC(=C2)N3CCCC(C3)CO)F)C)C(=O)O Chemical class CC1=CC(=CC(=C1N=CC2=C(C=CC(=C2)N3CCCC(C3)CO)F)C)C(=O)O BKOMJKYHNLXHQO-UHFFFAOYSA-N 0.000 description 2
- DWLQFNDQSFADOV-UHFFFAOYSA-N CCCCC(CCCC)(CCCC)CCCCCCCCC(C)(C)OCC1CCCNC1 Chemical compound CCCCC(CCCC)(CCCC)CCCCCCCCC(C)(C)OCC1CCCNC1 DWLQFNDQSFADOV-UHFFFAOYSA-N 0.000 description 2
- ZDEBEHNBQIRSDL-UHFFFAOYSA-N CCCCCCCCC(CCCC)C(C)(C)OCC1CCNC1 Chemical compound CCCCCCCCC(CCCC)C(C)(C)OCC1CCNC1 ZDEBEHNBQIRSDL-UHFFFAOYSA-N 0.000 description 2
- 229910016523 CuKa Inorganic materials 0.000 description 2
- 102100038496 Cysteinyl leukotriene receptor 1 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000882759 Homo sapiens Cysteinyl leukotriene receptor 1 Proteins 0.000 description 2
- 101001009517 Homo sapiens Probable G-protein coupled receptor 32 Proteins 0.000 description 2
- 101000836978 Homo sapiens Sperm-associated antigen 11B Proteins 0.000 description 2
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102100030321 Probable G-protein coupled receptor 32 Human genes 0.000 description 2
- 101150109738 Ptger4 gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- OWGUSBISUVLUJF-SDNWHVSQSA-N [(e)-(2-hexylcyclopentylidene)amino]thiourea Chemical compound CCCCCCC1CCC\C1=N/NC(N)=S OWGUSBISUVLUJF-SDNWHVSQSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 102000052785 human PTGER1 Human genes 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- YSUYMIMLCZOBJX-UHFFFAOYSA-N methyl 2,4-dimethyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(C)C([N+]([O-])=O)=C1C YSUYMIMLCZOBJX-UHFFFAOYSA-N 0.000 description 2
- IQUHJQRBKOPNQC-UHFFFAOYSA-N methyl 3,5-dimethyl-4-nitrobenzoate Chemical compound COC(=O)C1=CC(C)=C([N+]([O-])=O)C(C)=C1 IQUHJQRBKOPNQC-UHFFFAOYSA-N 0.000 description 2
- PEVXENGLERTHJE-UHFFFAOYSA-N methyl 3,5-dimethylbenzoate Chemical compound COC(=O)C1=CC(C)=CC(C)=C1 PEVXENGLERTHJE-UHFFFAOYSA-N 0.000 description 2
- ISGOBJKTOCHBHN-UHFFFAOYSA-N methyl 3-[(2-chloroquinoline-4-carbonyl)amino]-2,4-dimethylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(NC(=O)C=2C3=CC=CC=C3N=C(Cl)C=2)=C1C ISGOBJKTOCHBHN-UHFFFAOYSA-N 0.000 description 2
- FSUBBXAIDUYTFZ-UHFFFAOYSA-N methyl 3-[[2-(4-hydroxypiperidin-1-yl)quinoline-4-carbonyl]amino]-2,4-dimethylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(NC(=O)C=2C3=CC=CC=C3N=C(C=2)N2CCC(O)CC2)=C1C FSUBBXAIDUYTFZ-UHFFFAOYSA-N 0.000 description 2
- NKJRFIVHKHIRCG-UHFFFAOYSA-N methyl 4-[(2-chloroquinoline-4-carbonyl)amino]-3,5-dimethylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC(C)=C1NC(=O)C1=CC(Cl)=NC2=CC=CC=C12 NKJRFIVHKHIRCG-UHFFFAOYSA-N 0.000 description 2
- FNEWCPLEGFHFIN-UHFFFAOYSA-N methyl 4-[[2-(4-hydroxypiperidin-1-yl)quinoline-4-carbonyl]amino]-3,5-dimethylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC(C)=C1NC(=O)C1=CC(N2CCC(O)CC2)=NC2=CC=CC=C12 FNEWCPLEGFHFIN-UHFFFAOYSA-N 0.000 description 2
- DKKIOCYBDVCUHZ-UHFFFAOYSA-N methyl 4-[[6-[3-(hydroxymethyl)pyrrolidin-1-yl]-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC(C)=C1NC(=O)C1=NC(N2CC(CO)CC2)=CC=C1C DKKIOCYBDVCUHZ-UHFFFAOYSA-N 0.000 description 2
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229940075993 receptor modulator Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- HDFQKJQEWGVKCQ-UHFFFAOYSA-N 1,3-dimethyl-2-nitrobenzene Chemical compound CC1=CC=CC(C)=C1[N+]([O-])=O HDFQKJQEWGVKCQ-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- RBAVFNOGEPCOQI-UHFFFAOYSA-N 3,5-dimethyl-4-nitrobenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(C)=C1[N+]([O-])=O RBAVFNOGEPCOQI-UHFFFAOYSA-N 0.000 description 1
- MJMMAWQQRHBTDP-UHFFFAOYSA-N 3-[[2-(4-hydroxypiperidin-1-yl)quinoline-4-carbonyl]amino]-2,4-dimethylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(C)=C1NC(=O)C1=CC(N2CCC(O)CC2)=NC2=CC=CC=C12 MJMMAWQQRHBTDP-UHFFFAOYSA-N 0.000 description 1
- DMKYRXNSYOVNLS-UHFFFAOYSA-N 3-[[6-(4-hydroxy-4-methylpiperidin-1-yl)-3-methylpyridine-2-carbonyl]amino]-2,4-dimethylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(C)=C1NC(=O)C1=NC(N2CCC(C)(O)CC2)=CC=C1C DMKYRXNSYOVNLS-UHFFFAOYSA-N 0.000 description 1
- ZDHQJPREGUPRSG-UHFFFAOYSA-N 3-[[6-(4-hydroxypiperidin-1-yl)-3-methylpyridine-2-carbonyl]amino]-2,4-dimethylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(C)=C1NC(=O)C1=NC(N2CCC(O)CC2)=CC=C1C ZDHQJPREGUPRSG-UHFFFAOYSA-N 0.000 description 1
- BVLDTCPPYOKJCV-UHFFFAOYSA-N 3-[[6-[3-(hydroxymethyl)piperidin-1-yl]-3-methylpyridine-2-carbonyl]amino]-2,4-dimethylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(C)=C1NC(=O)C1=NC(N2CC(CO)CCC2)=CC=C1C BVLDTCPPYOKJCV-UHFFFAOYSA-N 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- JCTRNVCTGCQZAH-UHFFFAOYSA-N 4-[[2-(4-hydroxypiperidin-1-yl)quinoline-4-carbonyl]amino]-3,5-dimethylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(C)=C1NC(=O)C1=CC(N2CCC(O)CC2)=NC2=CC=CC=C12 JCTRNVCTGCQZAH-UHFFFAOYSA-N 0.000 description 1
- BRCZKOAZCVSKRY-UHFFFAOYSA-N 4-[[6-(4,4-difluoropiperidin-1-yl)-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoic acid Chemical compound CC1=CC=C(N2CCC(F)(F)CC2)N=C1C(=O)NC1=C(C)C=C(C(O)=O)C=C1C BRCZKOAZCVSKRY-UHFFFAOYSA-N 0.000 description 1
- RTDXITZEQPBLLI-UHFFFAOYSA-N 4-[[6-(4-hydroxy-4-methylpiperidin-1-yl)-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoic acid Chemical compound CC1=CC=C(N2CCC(C)(O)CC2)N=C1C(=O)NC1=C(C)C=C(C(O)=O)C=C1C RTDXITZEQPBLLI-UHFFFAOYSA-N 0.000 description 1
- LQAIPPASZQPMMK-UHFFFAOYSA-N 4-[[6-(4-methoxypiperidin-1-yl)-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoic acid Chemical compound C1CC(OC)CCN1C1=CC=C(C)C(C(=O)NC=2C(=CC(=CC=2C)C(O)=O)C)=N1 LQAIPPASZQPMMK-UHFFFAOYSA-N 0.000 description 1
- FRRVNUMGKQGXOM-UHFFFAOYSA-N 4-[[6-[3-(hydroxymethyl)piperidin-1-yl]-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(C)=C1NC(=O)C1=NC(N2CC(CO)CCC2)=CC=C1C FRRVNUMGKQGXOM-UHFFFAOYSA-N 0.000 description 1
- ZGZZLMPQKBZVQE-UHFFFAOYSA-N 4-[[6-[3-(hydroxymethyl)pyrrolidin-1-yl]-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoic acid Chemical compound CC1=CC=C(N2CC(CO)CC2)N=C1C(=O)NC1=C(C)C=C(C(O)=O)C=C1C ZGZZLMPQKBZVQE-UHFFFAOYSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- YJJCSLRNAPPQTH-UHFFFAOYSA-N C1C(=C2C=CC=CC2=CC1(N)Br)C(=O)O Chemical compound C1C(=C2C=CC=CC2=CC1(N)Br)C(=O)O YJJCSLRNAPPQTH-UHFFFAOYSA-N 0.000 description 1
- DRHGZHDIILXORT-UHFFFAOYSA-N CC(C=C1)=C(C=NC(C(C)=C2)=C(C)C=C2C(OC)=O)C=C1N1CC(CO)CCC1 Chemical compound CC(C=C1)=C(C=NC(C(C)=C2)=C(C)C=C2C(OC)=O)C=C1N1CC(CO)CCC1 DRHGZHDIILXORT-UHFFFAOYSA-N 0.000 description 1
- DPLOBMFREMXOSS-UHFFFAOYSA-N CC(C=C1)=C(C=NC2=C(C)C=CC(C(OC)=O)=C2C)C=C1N1CC(CO)CCC1 Chemical compound CC(C=C1)=C(C=NC2=C(C)C=CC(C(OC)=O)=C2C)C=C1N1CC(CO)CCC1 DPLOBMFREMXOSS-UHFFFAOYSA-N 0.000 description 1
- OVWJHKVYNHUJDJ-UHFFFAOYSA-N CC1=C(C(=C(C=C1)C(=O)OC)C)NC Chemical compound CC1=C(C(=C(C=C1)C(=O)OC)C)NC OVWJHKVYNHUJDJ-UHFFFAOYSA-N 0.000 description 1
- BIMBCBPMIQUEJJ-UHFFFAOYSA-N CC1=C(C(=C(C=C1)C(=O)OC)C)NC2=CC(=CC3=CC=CC=C32)Br Chemical compound CC1=C(C(=C(C=C1)C(=O)OC)C)NC2=CC(=CC3=CC=CC=C32)Br BIMBCBPMIQUEJJ-UHFFFAOYSA-N 0.000 description 1
- ZHHLLNMXTBBNHX-UHFFFAOYSA-N CC1=C(C(=C(C=C1)C(=O)OC)C)NC2=CC(=CC3=CC=CC=C32)N4CCC(CC4)O Chemical compound CC1=C(C(=C(C=C1)C(=O)OC)C)NC2=CC(=CC3=CC=CC=C32)N4CCC(CC4)O ZHHLLNMXTBBNHX-UHFFFAOYSA-N 0.000 description 1
- BBFZXFUUVHMANH-UHFFFAOYSA-N CC1=CC(=CC(=C1N=CC2=C(C=CC(=C2)N3CCCC(C3)CO)F)C)C(=O)OC Chemical compound CC1=CC(=CC(=C1N=CC2=C(C=CC(=C2)N3CCCC(C3)CO)F)C)C(=O)OC BBFZXFUUVHMANH-UHFFFAOYSA-N 0.000 description 1
- YRSVPWWDMDUTJB-UHFFFAOYSA-N CCC1=C(C=C(C=C1C(=O)OCC)C)C Chemical compound CCC1=C(C=C(C=C1C(=O)OCC)C)C YRSVPWWDMDUTJB-UHFFFAOYSA-N 0.000 description 1
- JUQMWHLFDAMHJA-UHFFFAOYSA-N CCCCCCCCC(CCCC)C(C)(C)OC1CCCNC1 Chemical compound CCCCCCCCC(CCCC)C(C)(C)OC1CCCNC1 JUQMWHLFDAMHJA-UHFFFAOYSA-N 0.000 description 1
- CPNNBGSTYMXRKM-UHFFFAOYSA-N CCCCCCCCC(CCCC)C(C)(C)OCC1CCCNC1 Chemical compound CCCCCCCCC(CCCC)C(C)(C)OCC1CCCNC1 CPNNBGSTYMXRKM-UHFFFAOYSA-N 0.000 description 1
- FHOXSQNJKHFDFL-UHFFFAOYSA-N CCCCCCCCCC(C)(C(C)(C)C)OCC1CCCNC1 Chemical compound CCCCCCCCCC(C)(C(C)(C)C)OCC1CCCNC1 FHOXSQNJKHFDFL-UHFFFAOYSA-N 0.000 description 1
- CUOSLWHWUVDBMQ-UHFFFAOYSA-N CCCCCCCCCC(C)(C)OC1CCNCC1 Chemical compound CCCCCCCCCC(C)(C)OC1CCNCC1 CUOSLWHWUVDBMQ-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 101710096361 Prostaglandin E synthase Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YPZCBIBAAUBMLB-UHFFFAOYSA-N ethyl 2,3-dimethylbenzoate Chemical compound CCOC(=O)C1=CC=CC(C)=C1C YPZCBIBAAUBMLB-UHFFFAOYSA-N 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- XSXVXSCMWUJXOS-UHFFFAOYSA-N ethyl 2-ethylbenzoate Chemical compound CCOC(=O)C1=CC=CC=C1CC XSXVXSCMWUJXOS-UHFFFAOYSA-N 0.000 description 1
- OWUHDTVMENUXMW-UHFFFAOYSA-N ethyl 4-[[6-(4-hydroxypiperidin-1-yl)-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoate Chemical compound CC1=CC(C(=O)OCC)=CC(C)=C1NC(=O)C1=NC(N2CCC(O)CC2)=CC=C1C OWUHDTVMENUXMW-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QFOYYQIUDDTVOT-UHFFFAOYSA-N methyl 3-[(3-bromonaphthalene-1-carbonyl)amino]-2,4-dimethylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(NC(=O)C=2C3=CC=CC=C3C=C(Br)C=2)=C1C QFOYYQIUDDTVOT-UHFFFAOYSA-N 0.000 description 1
- UEDKSAISISCOGO-UHFFFAOYSA-N methyl 3-[[6-(4-hydroxypiperidin-1-yl)-3-methylpyridine-2-carbonyl]amino]-2,4-dimethylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(NC(=O)C=2C(=CC=C(N=2)N2CCC(O)CC2)C)=C1C UEDKSAISISCOGO-UHFFFAOYSA-N 0.000 description 1
- KZRROEKZRNUUKK-UHFFFAOYSA-N methyl 3-[[6-[3-(hydroxymethyl)piperidin-1-yl]-3-methylpyridine-2-carbonyl]amino]-2,4-dimethylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(NC(=O)C=2C(=CC=C(N=2)N2CC(CO)CCC2)C)=C1C KZRROEKZRNUUKK-UHFFFAOYSA-N 0.000 description 1
- VXCDYRLZDFQUCJ-UHFFFAOYSA-N methyl 3-amino-2,4-dimethylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(N)=C1C VXCDYRLZDFQUCJ-UHFFFAOYSA-N 0.000 description 1
- CHALVWOTAVMTFK-UHFFFAOYSA-N methyl 4-[[6-(4,4-difluoropiperidin-1-yl)-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC(C)=C1NC(=O)C1=NC(N2CCC(F)(F)CC2)=CC=C1C CHALVWOTAVMTFK-UHFFFAOYSA-N 0.000 description 1
- TZEHCOWHWBTMCF-UHFFFAOYSA-N methyl 4-[[6-(4-methoxypiperidin-1-yl)-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoate Chemical compound C1CC(OC)CCN1C1=CC=C(C)C(C(=O)NC=2C(=CC(=CC=2C)C(=O)OC)C)=N1 TZEHCOWHWBTMCF-UHFFFAOYSA-N 0.000 description 1
- YTPAWTSBBDELOH-UHFFFAOYSA-N methyl 4-[[6-[3-(hydroxymethyl)piperidin-1-yl]-3-methylpyridine-2-carbonyl]amino]-3,5-dimethylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC(C)=C1NC(=O)C1=NC(N2CC(CO)CCC2)=CC=C1C YTPAWTSBBDELOH-UHFFFAOYSA-N 0.000 description 1
- QKXXURVZIZZZEW-UHFFFAOYSA-N methyl 5-amino-3,5-dimethylcyclohexa-1,3-diene-1-carboxylate Chemical compound COC(=O)C1=CC(C)=CC(C)(N)C1 QKXXURVZIZZZEW-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002740 neurokinin 3 receptor antagonist Substances 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- VUNPWIPIOOMCPT-UHFFFAOYSA-N piperidin-3-ylmethanol Chemical compound OCC1CCCNC1 VUNPWIPIOOMCPT-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- IUTZJUYLKWNRJT-UHFFFAOYSA-M potassium;6-chloro-3-methylpyridine-2-carboxylate Chemical compound [K+].CC1=CC=C(Cl)N=C1C([O-])=O IUTZJUYLKWNRJT-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665956P | 2012-06-29 | 2012-06-29 | |
| US201361778969P | 2013-03-13 | 2013-03-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201410665A TW201410665A (zh) | 2014-03-16 |
| TWI572597B true TWI572597B (zh) | 2017-03-01 |
Family
ID=48746667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102120796A TWI572597B (zh) | 2012-06-29 | 2013-06-11 | 二甲基－苯甲酸化合物 |
Country Status (40)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI641583B (zh) * | 2013-02-07 | 2018-11-21 | 奧米羅有限公司 | 具有ep4受體活性的經取代之苯甲醯胺 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110015221A1 (en) * | 2003-12-23 | 2011-01-20 | Pierre Fabre Medicament | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| TWI572597B (zh) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| JP6200596B2 (ja) | 2013-12-17 | 2017-09-20 | イーライ リリー アンド カンパニー | ジメチル安息香酸化合物 |
| US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| PE20191616A1 (es) * | 2017-04-10 | 2019-11-05 | Bayer Ag | N-ariletil-2-arilquinolina-4-carboxamidas sustituidas y su uso |
| TWI770157B (zh) * | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| JP7816164B2 (ja) | 2020-11-13 | 2026-02-18 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090105321A1 (en) * | 2006-06-12 | 2009-04-23 | Michael Boyd | Indole Amide Derivatives as Ep4 Receptot Ligands |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270615B (it) | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
| JP2000355551A (ja) * | 1999-06-15 | 2000-12-26 | Nikken Chem Co Ltd | 医薬組成物 |
| MXPA06003123A (es) | 2003-09-22 | 2006-05-31 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor. |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| KR20090122931A (ko) * | 2007-03-26 | 2009-12-01 | 아스테라스 세이야쿠 가부시키가이샤 | 오르니틴 유도체 |
| WO2012004293A2 (de) | 2010-07-08 | 2012-01-12 | Bayer Cropscience Ag | Insektizide und fungizide wirkstoffkombinationen |
| CA2831978A1 (en) | 2011-03-03 | 2012-09-07 | Universitat Des Saarlandes | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| TWI572597B (zh) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
-
2013
- 2013-06-11 TW TW102120796A patent/TWI572597B/zh not_active IP Right Cessation
- 2013-06-13 AR ARP130102078 patent/AR091431A1/es unknown
- 2013-06-13 JO JOP/2013/0178A patent/JO3221B1/ar active
- 2013-06-20 SI SI201330576A patent/SI2867218T1/sl unknown
- 2013-06-20 MX MX2014015952A patent/MX347476B/es active IP Right Grant
- 2013-06-20 PL PL13734249T patent/PL2867218T3/pl unknown
- 2013-06-20 AP AP2014008165A patent/AP4063A/en active
- 2013-06-20 ES ES13734249.9T patent/ES2623099T3/es active Active
- 2013-06-20 SG SG11201408629QA patent/SG11201408629QA/en unknown
- 2013-06-20 EA EA201492140A patent/EA025531B1/ru not_active IP Right Cessation
- 2013-06-20 ME MEP-2017-83A patent/ME02655B/me unknown
- 2013-06-20 IN IN2356MUN2014 patent/IN2014MN02356A/en unknown
- 2013-06-20 PT PT137342499T patent/PT2867218T/pt unknown
- 2013-06-20 LT LTEP13734249.9T patent/LT2867218T/lt unknown
- 2013-06-20 PE PE2014002531A patent/PE20150185A1/es active IP Right Grant
- 2013-06-20 DK DK13734249.9T patent/DK2867218T3/en active
- 2013-06-20 NZ NZ701894A patent/NZ701894A/en not_active IP Right Cessation
- 2013-06-20 RS RS20170231A patent/RS55756B1/sr unknown
- 2013-06-20 US US13/922,277 patent/US8642768B2/en not_active Expired - Fee Related
- 2013-06-20 CA CA2875572A patent/CA2875572C/en not_active Expired - Fee Related
- 2013-06-20 HR HRP20170540TT patent/HRP20170540T1/hr unknown
- 2013-06-20 BR BR112014029551A patent/BR112014029551A2/pt not_active IP Right Cessation
- 2013-06-20 EP EP13734249.9A patent/EP2867218B1/en active Active
- 2013-06-20 KR KR1020147036136A patent/KR101634032B1/ko not_active Expired - Fee Related
- 2013-06-20 CN CN201380030138.XA patent/CN104334540B/zh not_active Expired - Fee Related
- 2013-06-20 MY MYPI2014703973A patent/MY172860A/en unknown
- 2013-06-20 AU AU2013280779A patent/AU2013280779B2/en not_active Ceased
- 2013-06-20 HU HUE13734249A patent/HUE032398T2/en unknown
- 2013-06-20 JP JP2015520305A patent/JP6114824B2/ja active Active
- 2013-06-20 WO PCT/US2013/046685 patent/WO2014004230A1/en not_active Ceased
- 2013-12-04 US US14/096,469 patent/US8933098B2/en not_active Expired - Fee Related
-
2014
- 2014-11-24 ZA ZA2014/08631A patent/ZA201408631B/en unknown
- 2014-11-28 TN TN2014000500A patent/TN2014000500A1/fr unknown
- 2014-12-03 CR CR20140554A patent/CR20140554A/es unknown
- 2014-12-11 IL IL236218A patent/IL236218A/en active IP Right Grant
- 2014-12-17 GT GT201400289A patent/GT201400289A/es unknown
- 2014-12-17 DO DO2014000286A patent/DOP2014000286A/es unknown
- 2014-12-18 CO CO14278424A patent/CO7160064A2/es unknown
- 2014-12-26 CL CL2014003537A patent/CL2014003537A1/es unknown
-
2015
- 2015-01-05 PH PH12015500008A patent/PH12015500008B1/en unknown
-
2017
- 2017-04-12 CY CY20171100435T patent/CY1118830T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090105321A1 (en) * | 2006-06-12 | 2009-04-23 | Michael Boyd | Indole Amide Derivatives as Ep4 Receptot Ligands |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI641583B (zh) * | 2013-02-07 | 2018-11-21 | 奧米羅有限公司 | 具有ep4受體活性的經取代之苯甲醯胺 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201410665A (zh) | 二甲基－苯甲酸化合物 | |
| CN104411684B (zh) | 苯氧基乙基哌啶化合物 | |
| ES2297205T3 (es) | Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica. | |
| TWI691488B (zh) | ３,４-二氫異喹啉-２（１ｈ）-基化合物 | |
| EP1735278B1 (en) | Histamine h3 receptor agents, preparation and therapeutic uses | |
| CN101151244B (zh) | 组胺h3受体活性剂、制备和治疗用途 | |
| TWI636046B (zh) | 苯氧基乙基二氫－１ｈ－異喹啉化合物 | |
| RS51888B (sr) | N-(fenil(piperidin-2-il)metil)benzamidni derivati, njihovo dobijanje i njihova primena u terapiji | |
| JP2009524628A (ja) | スルホンアミド誘導体、これの調製法およびこれのオレキシン２受容体のアンタゴニストとしての使用 | |
| CN108430969B (zh) | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 | |
| PT2358676E (pt) | Forma cristalina de um composto 4-[2-(2-fluorofenoximetil)fenil]piperidina | |
| EP1638934B1 (en) | 3-aminopyrrolidines as inhibitors of monoamine uptake | |
| EP3083595A1 (en) | Piperidine compounds having multimodal activity against pain | |
| BR112015009243A2 (pt) | composto de amina cíclico fluorosubstituído, método para preparar um composto de amina cíclico fluorosubstituído, composição farmacêutica, inibidor de acetilcolinesterase e uso do composto de amina cíclico fluorosubstituído | |
| JP2013075894A (ja) | Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩からなる医薬 | |
| JP5052497B2 (ja) | ヒスタミンｈ３受容体アンタゴニストとしてのピロリジン誘導体 | |
| EP1904442B1 (en) | Histamine h3 receptor agents, preparation and therapeutic uses | |
| CN121794256A (zh) | 作为gpr183拮抗剂用于治疗慢性疼痛的2-苯氧基-1-(4-(烷基磺酰基)哌啶-1-基)乙-1-酮和3-苯基-1-(4-(烷基磺酰基)哌啶-1-基)丙-2-烯-1-酮衍生物 | |
| CN1956952B (zh) | 组胺h3受体药剂、制备和治疗学用途 | |
| WO2024125346A1 (zh) | 氘代的4-苯基哌啶-4-醇类化合物的制备及其用途 | |
| HK1203936B (en) | Dimethyl-benzoic acid compounds useful for the treatment of inflammatory conditions | |
| JP2004168772A (ja) | 受容体調節剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |